CapsoVision（H6U）株式概要CapsoVision, Inc.は医療技術企業で、消化器系の内部画像診断に特化した内視鏡ビデオ画像診断装置を製造・販売している。 詳細H6U ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長2/6過去の実績0/6財務の健全性6/6配当金0/6報酬収益は年間24.98%増加すると予測されています 過去 1 年間で収益は11%増加しましたリスク分析German市場と比較して、過去 3 か月間の株価の変動が非常に大きい現在は利益が出ておらず、今後3年間で利益が出る見込みはない すべてのリスクチェックを見るH6U Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW467,536 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA467,536 investors already sharing narrativesYour Fair Value€Current Price€4.90282.8% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-30m42m2016201920222025202620282031Revenue US$42.4mEarnings US$5.6mAdvancedSet Fair ValueView all narrativesCapsoVision, Inc. 競合他社StratecSymbol: XTRA:SBSMarket cap: €263.2mEckert & ZieglerSymbol: XTRA:EUZMarket cap: €854.2mRedsense MedicalSymbol: DB:R0ZMarket cap: €57.7mDrägerwerk KGaASymbol: XTRA:DRW3Market cap: €1.8b価格と性能株価の高値、安値、推移の概要CapsoVision過去の株価現在の株価US$4.9052週高値US$12.8552週安値US$3.70ベータ01ヶ月の変化-8.41%3ヶ月変化-9.26%1年変化n/a3年間の変化n/a5年間の変化n/aIPOからの変化-2.84%最新ニュースReported Earnings • Aug 16Second quarter 2026 earnings released: US$0.15 loss per share (vs US$2.02 loss in 2Q 2025)Second quarter 2026 results: US$0.15 loss per share. Revenue: US$3.64m (up 9.9% from 2Q 2025). Net loss: US$7.48m (loss widened 62% from 2Q 2025). Revenue is forecast to grow 25% p.a. on average during the next 2 years, compared to a 6.0% growth forecast for the Medical Equipment industry in Germany.お知らせ • Aug 14CapsoVision, Inc. Provides Revenue Guidance for the Second Half of 2026CapsoVision, Inc. provided revenue guidance for the second half of 2026. The company expects revenue in the second half of the year to be higher than in the first half.お知らせ • Aug 05CapsoVision Announces International Launch of AI Highlights for CapsoCam Plus SystemCapsoVision announced the international launch of AI Highlights for the CapsoCam Plus system. AI Highlights is available within CapsoView and is being introduced in international markets, including the European Union. AI Highlights is designed to support physician review of small bowel capsule endoscopy studies by identifying frames containing suspected clinically relevant findings during the standard video processing workflow. It integrates with CapsoView, CapsoVision's video processing and review software, and supports workflows connected to the Company's CapsoCloud platform. During video processing, the AI algorithm analyzes frames captured by the CapsoCam Plus capsule and identifies frames with suspected clinically relevant findings for physician review. These AI-processed videos may then be reviewed within either CapsoView or CapsoCloud, depending on workflow configuration. AI Highlights is designed to identify and organize frames with suspected clinically relevant findings to support physician assessment as part of the complete study. Where and when available, CapsoCloud enables organizations to securely access AI-processed videos for remote physician review, collaboration, and case management. Depending on workflow configuration and regional availability, studies processed in CapsoView may be securely uploaded to CapsoCloud to support these workflows. AI Highlights is intended to be used by trained healthcare professionals and is not intended to replace clinical judgment. Please refer to the product's Instructions for Use for complete information regarding indications, contraindications, warnings, precautions, and limitations. AI Highlights is being offered as an update to CapsoView and, where applicable, CapsoCloud in markets where these products are authorized for use under applicable regulatory requirements, including the European Union under the Medical Device Regulation (MDR). AI Highlights has not been cleared by the U.S. Food and Drug Administration and is not available for sale in the United States. The Company's portfolio also includes AI Highlights, an AI-assisted workflow feature designed to support physician review of small bowel capsule endoscopy studies. CapsoVision continues to advance its capsule endoscopy platform with AI-assisted capabilities designed to support physician workflow and streamline clinical review. Its next pipeline product, CapsoCam Colon, powered by advanced AI-driven polyp detection, is designed to enable non-invasive colon imaging. With a proprietary platform targeted to expand across multiple GI indications, including esophageal and pancreatic disorders, CapsoVision is advancing a new era in capsule-based diagnostics.Board Change • Aug 04High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director David Shields was the last director to join the board, commencing their role in 2026. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.お知らせ • Jul 31CapsoVision, Inc. to Report Q2, 2026 Results on Aug 13, 2026CapsoVision, Inc. announced that they will report Q2, 2026 results After-Market on Aug 13, 2026お知らせ • Jul 03CapsoVision, Inc. Announces Board and Committee Changes, Effective July 1, 2026CapsoVision, Inc. announced that on July 1, 2026, the Board of Directors appointed Dr. David Stanley Shields to serve as a Class I director of the Board and as a member of the Compensation Committee of the Board, in each case effective July 1, 2026, to fill the vacancy upon the resignation of Dr. Joanne Imperial. Dr. David S. Shields, age 75, is a board-certified gastroenterologist with more than four decades of experience in academic medicine, clinical gastroenterology, advanced endoscopy, and digestive disease management. Since 1986, he has maintained a private gastroenterology consulting practice in Palo Alto, California, providing comprehensive care to patients with gastrointestinal and liver disorders. Dr. Shields previously served as Assistant Professor of Medicine in the Division of Gastroenterology at Stanford University School of Medicine and served as Director of Endoscopy at Stanford Hospital. Throughout his career, he has remained actively involved in clinical education and physician training. He currently serves as a gastroenterology consultant and clinician at both San Mateo County Medical Center and the Palo Alto Veterans Affairs Health Care System, where he continues to teach medical residents and gastroenterology fellows. Dr. Shields established one of the earliest gastroenterology endoscopy programs associated with Stanford University and has been an early adopter and clinical investigator in capsule endoscopy technology. He has accumulated nearly two decades of experience utilizing capsule endoscopy for the diagnosis and management of small bowel disorders and gastrointestinal bleeding. Dr. Shields earned a Bachelor of Arts degree in Biochemistry with highest honors from the University of California, Santa Barbara, and received his Doctor of Medicine degree from the University of California, San Francisco School of Medicine. He completed his residency training in Internal Medicine at Stanford University School of Medicine and the University of Virginia, followed by a fellowship in Gastroenterology at the University of Virginia. The Board determined that Dr. Shields is an independent director of the Board, and that he satisfies all applicable requirements to serve on the Compensation Committee, including without limitation the applicable requirements of The Nasdaq Stock Market LLC and the Securities Exchange Act of 1934, as amended. On July 1, 2026, Dr. Joanne Imperial stepped down from the Board as a Class I director and as a member of the Compensation Committee of the Board, effective July 1, 2026. Dr. Imperial's decision to resign was not the result of any disagreement with the management or the Board on any matter relating to the Company's operations, policies or practices. Dr. Imperial will continue to serve the Company as an independent consultant.最新情報をもっと見るRecent updatesReported Earnings • Aug 16Second quarter 2026 earnings released: US$0.15 loss per share (vs US$2.02 loss in 2Q 2025)Second quarter 2026 results: US$0.15 loss per share. Revenue: US$3.64m (up 9.9% from 2Q 2025). Net loss: US$7.48m (loss widened 62% from 2Q 2025). Revenue is forecast to grow 25% p.a. on average during the next 2 years, compared to a 6.0% growth forecast for the Medical Equipment industry in Germany.お知らせ • Aug 14CapsoVision, Inc. Provides Revenue Guidance for the Second Half of 2026CapsoVision, Inc. provided revenue guidance for the second half of 2026. The company expects revenue in the second half of the year to be higher than in the first half.お知らせ • Aug 05CapsoVision Announces International Launch of AI Highlights for CapsoCam Plus SystemCapsoVision announced the international launch of AI Highlights for the CapsoCam Plus system. AI Highlights is available within CapsoView and is being introduced in international markets, including the European Union. AI Highlights is designed to support physician review of small bowel capsule endoscopy studies by identifying frames containing suspected clinically relevant findings during the standard video processing workflow. It integrates with CapsoView, CapsoVision's video processing and review software, and supports workflows connected to the Company's CapsoCloud platform. During video processing, the AI algorithm analyzes frames captured by the CapsoCam Plus capsule and identifies frames with suspected clinically relevant findings for physician review. These AI-processed videos may then be reviewed within either CapsoView or CapsoCloud, depending on workflow configuration. AI Highlights is designed to identify and organize frames with suspected clinically relevant findings to support physician assessment as part of the complete study. Where and when available, CapsoCloud enables organizations to securely access AI-processed videos for remote physician review, collaboration, and case management. Depending on workflow configuration and regional availability, studies processed in CapsoView may be securely uploaded to CapsoCloud to support these workflows. AI Highlights is intended to be used by trained healthcare professionals and is not intended to replace clinical judgment. Please refer to the product's Instructions for Use for complete information regarding indications, contraindications, warnings, precautions, and limitations. AI Highlights is being offered as an update to CapsoView and, where applicable, CapsoCloud in markets where these products are authorized for use under applicable regulatory requirements, including the European Union under the Medical Device Regulation (MDR). AI Highlights has not been cleared by the U.S. Food and Drug Administration and is not available for sale in the United States. The Company's portfolio also includes AI Highlights, an AI-assisted workflow feature designed to support physician review of small bowel capsule endoscopy studies. CapsoVision continues to advance its capsule endoscopy platform with AI-assisted capabilities designed to support physician workflow and streamline clinical review. Its next pipeline product, CapsoCam Colon, powered by advanced AI-driven polyp detection, is designed to enable non-invasive colon imaging. With a proprietary platform targeted to expand across multiple GI indications, including esophageal and pancreatic disorders, CapsoVision is advancing a new era in capsule-based diagnostics.Board Change • Aug 04High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director David Shields was the last director to join the board, commencing their role in 2026. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.お知らせ • Jul 31CapsoVision, Inc. to Report Q2, 2026 Results on Aug 13, 2026CapsoVision, Inc. announced that they will report Q2, 2026 results After-Market on Aug 13, 2026お知らせ • Jul 03CapsoVision, Inc. Announces Board and Committee Changes, Effective July 1, 2026CapsoVision, Inc. announced that on July 1, 2026, the Board of Directors appointed Dr. David Stanley Shields to serve as a Class I director of the Board and as a member of the Compensation Committee of the Board, in each case effective July 1, 2026, to fill the vacancy upon the resignation of Dr. Joanne Imperial. Dr. David S. Shields, age 75, is a board-certified gastroenterologist with more than four decades of experience in academic medicine, clinical gastroenterology, advanced endoscopy, and digestive disease management. Since 1986, he has maintained a private gastroenterology consulting practice in Palo Alto, California, providing comprehensive care to patients with gastrointestinal and liver disorders. Dr. Shields previously served as Assistant Professor of Medicine in the Division of Gastroenterology at Stanford University School of Medicine and served as Director of Endoscopy at Stanford Hospital. Throughout his career, he has remained actively involved in clinical education and physician training. He currently serves as a gastroenterology consultant and clinician at both San Mateo County Medical Center and the Palo Alto Veterans Affairs Health Care System, where he continues to teach medical residents and gastroenterology fellows. Dr. Shields established one of the earliest gastroenterology endoscopy programs associated with Stanford University and has been an early adopter and clinical investigator in capsule endoscopy technology. He has accumulated nearly two decades of experience utilizing capsule endoscopy for the diagnosis and management of small bowel disorders and gastrointestinal bleeding. Dr. Shields earned a Bachelor of Arts degree in Biochemistry with highest honors from the University of California, Santa Barbara, and received his Doctor of Medicine degree from the University of California, San Francisco School of Medicine. He completed his residency training in Internal Medicine at Stanford University School of Medicine and the University of Virginia, followed by a fellowship in Gastroenterology at the University of Virginia. The Board determined that Dr. Shields is an independent director of the Board, and that he satisfies all applicable requirements to serve on the Compensation Committee, including without limitation the applicable requirements of The Nasdaq Stock Market LLC and the Securities Exchange Act of 1934, as amended. On July 1, 2026, Dr. Joanne Imperial stepped down from the Board as a Class I director and as a member of the Compensation Committee of the Board, effective July 1, 2026. Dr. Imperial's decision to resign was not the result of any disagreement with the management or the Board on any matter relating to the Company's operations, policies or practices. Dr. Imperial will continue to serve the Company as an independent consultant.お知らせ • Jun 29+ 5 more updatesCapsoVision, Inc.(NasdaqCM:CV) dropped from Russell Small Cap Comp Value BenchmarkCapsoVision, Inc.(NasdaqCM:CV) dropped from Russell Small Cap Comp Value BenchmarkBoard Change • May 20High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Julia Gouw was the last director to join the board, commencing their role in 2025. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • May 20First quarter 2026 earnings released: US$0.15 loss per share (vs US$2.49 loss in 1Q 2025)First quarter 2026 results: US$0.15 loss per share. Revenue: US$2.79m (flat on 1Q 2025). Net loss: US$7.03m (loss widened 31% from 1Q 2025). Revenue is forecast to grow 27% p.a. on average during the next 2 years, compared to a 5.9% growth forecast for the Medical Equipment industry in Germany.お知らせ • May 02CapsoVision, Inc. to Report Q1, 2026 Results on May 14, 2026CapsoVision, Inc. announced that they will report Q1, 2026 results After-Market on May 14, 2026お知らせ • May 01CapsoVision, Inc., Annual General Meeting, Jun 11, 2026CapsoVision, Inc., Annual General Meeting, Jun 11, 2026.お知らせ • Mar 13CapsoVision, Inc. to Report Q4, 2025 Results on Mar 26, 2026CapsoVision, Inc. announced that they will report Q4, 2025 results After-Market on Mar 26, 2026お知らせ • Jan 01CapsoVision Announces 510(k) Submission for the Addition of AI-Assisted Reading Module in CapsoCam Plus®?CapsoVision, Inc. announced submission of its 510(k) application to the Food and Drug Administration (FDA) for its proprietary AI-assisted module for CapsoCam Plus®?. The addition of this reading tool will improve the detection of clinically significant pathology, as well as reduce clinician review time. The Company intends for U.S. commercialization activities to commence after the FDA clearance. CapsoVision's CapsoCam Plus capsule endoscopy system is intended for visualization of the small bowel mucosa to detect abnormalities of the small bowel in adults and children aged two years and older. The Company believes that it is a more advanced capsule endoscopy solution compared to competitor systems, both in how it captures and presents images of the GI tract and the clinical workflow and patient experience that it enables.株主還元H6UDE Medical EquipmentDE 市場7D-3.9%2.0%-0.6%1Yn/a-16.1%2.7%株主還元を見る業界別リターン: H6UがGerman Medical Equipment業界に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。リターン対市場: H6U German市場に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。価格変動Is H6U's price volatile compared to industry and market?H6U volatilityH6U Average Weekly Movement13.1%Medical Equipment Industry Average Movement5.2%Market Average Movement5.2%10% most volatile stocks in DE Market12.8%10% least volatile stocks in DE Market2.6%安定した株価: H6Uの株価は、 German市場と比較して過去 3 か月間で変動しています。時間の経過による変動: H6Uの 週次ボラティリティ は過去 1 年間で35%から13%に減少しましたが、依然としてGerman株の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト200599Johnny Wangcapsovision.comCapsoVision, Inc.は医療技術企業で、消化器系の体内画像診断に特化した内視鏡ビデオイメージング機器を製造・販売している。2歳以上の成人および小児の小腸粘膜を可視化するカプセル型内視鏡システムCapsoCam Plus、大腸の可視化とポリープの検出・計測を行うCapsoCam Colonを提供し、大腸用のCapsoColon 3Dも開発している。また、オフプレミスのビデオアクセスおよびダウンロードソリューションとして、クラウドベースのSaaS型エコシステム「CapsoCloud」、カプセルデータアクセスシステム「CapsoAccess」、カプセルビデオを閲覧するためのデータアクセス読取装置「CapsoView」、磁気ワンドを使用してカプセルを回収するための回収キット「CapsoRetrieve」、およびカプセルビデオ読取サービスを提供している。同社は消化器系の診療所、クリニック、病院を顧客としている。同社は製品を再販する代理店顧客に製品を販売している。同社は以前はカプソビジョン社として知られていたが、2016年5月にカプソビジョン社に社名を変更した。2005年に法人化され、カリフォルニア州サラトガに本社を置いている。もっと見るCapsoVision, Inc. 基礎のまとめCapsoVision の収益と売上を時価総額と比較するとどうか。H6U 基礎統計学時価総額€257.99m収益（TTM）-€25.54m売上高(TTM)€11.89m21.7xP/Sレシオ-10.1xPER（株価収益率H6U は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計H6U 損益計算書（TTM）収益US$13.89m売上原価US$6.82m売上総利益US$7.07mその他の費用US$36.90m収益-US$29.83m直近の収益報告Jun 30, 2026次回決算日該当なし一株当たり利益（EPS）-0.60グロス・マージン50.88%純利益率-214.74%有利子負債／自己資本比率0%H6U の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/23 00:52終値2026/08/21 00:00収益2026/06/30年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋CapsoVision, Inc. 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Bruce JacksonBenchmark Company
Reported Earnings • Aug 16Second quarter 2026 earnings released: US$0.15 loss per share (vs US$2.02 loss in 2Q 2025)Second quarter 2026 results: US$0.15 loss per share. Revenue: US$3.64m (up 9.9% from 2Q 2025). Net loss: US$7.48m (loss widened 62% from 2Q 2025). Revenue is forecast to grow 25% p.a. on average during the next 2 years, compared to a 6.0% growth forecast for the Medical Equipment industry in Germany.
お知らせ • Aug 14CapsoVision, Inc. Provides Revenue Guidance for the Second Half of 2026CapsoVision, Inc. provided revenue guidance for the second half of 2026. The company expects revenue in the second half of the year to be higher than in the first half.
お知らせ • Aug 05CapsoVision Announces International Launch of AI Highlights for CapsoCam Plus SystemCapsoVision announced the international launch of AI Highlights for the CapsoCam Plus system. AI Highlights is available within CapsoView and is being introduced in international markets, including the European Union. AI Highlights is designed to support physician review of small bowel capsule endoscopy studies by identifying frames containing suspected clinically relevant findings during the standard video processing workflow. It integrates with CapsoView, CapsoVision's video processing and review software, and supports workflows connected to the Company's CapsoCloud platform. During video processing, the AI algorithm analyzes frames captured by the CapsoCam Plus capsule and identifies frames with suspected clinically relevant findings for physician review. These AI-processed videos may then be reviewed within either CapsoView or CapsoCloud, depending on workflow configuration. AI Highlights is designed to identify and organize frames with suspected clinically relevant findings to support physician assessment as part of the complete study. Where and when available, CapsoCloud enables organizations to securely access AI-processed videos for remote physician review, collaboration, and case management. Depending on workflow configuration and regional availability, studies processed in CapsoView may be securely uploaded to CapsoCloud to support these workflows. AI Highlights is intended to be used by trained healthcare professionals and is not intended to replace clinical judgment. Please refer to the product's Instructions for Use for complete information regarding indications, contraindications, warnings, precautions, and limitations. AI Highlights is being offered as an update to CapsoView and, where applicable, CapsoCloud in markets where these products are authorized for use under applicable regulatory requirements, including the European Union under the Medical Device Regulation (MDR). AI Highlights has not been cleared by the U.S. Food and Drug Administration and is not available for sale in the United States. The Company's portfolio also includes AI Highlights, an AI-assisted workflow feature designed to support physician review of small bowel capsule endoscopy studies. CapsoVision continues to advance its capsule endoscopy platform with AI-assisted capabilities designed to support physician workflow and streamline clinical review. Its next pipeline product, CapsoCam Colon, powered by advanced AI-driven polyp detection, is designed to enable non-invasive colon imaging. With a proprietary platform targeted to expand across multiple GI indications, including esophageal and pancreatic disorders, CapsoVision is advancing a new era in capsule-based diagnostics.
Board Change • Aug 04High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director David Shields was the last director to join the board, commencing their role in 2026. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Jul 31CapsoVision, Inc. to Report Q2, 2026 Results on Aug 13, 2026CapsoVision, Inc. announced that they will report Q2, 2026 results After-Market on Aug 13, 2026
お知らせ • Jul 03CapsoVision, Inc. Announces Board and Committee Changes, Effective July 1, 2026CapsoVision, Inc. announced that on July 1, 2026, the Board of Directors appointed Dr. David Stanley Shields to serve as a Class I director of the Board and as a member of the Compensation Committee of the Board, in each case effective July 1, 2026, to fill the vacancy upon the resignation of Dr. Joanne Imperial. Dr. David S. Shields, age 75, is a board-certified gastroenterologist with more than four decades of experience in academic medicine, clinical gastroenterology, advanced endoscopy, and digestive disease management. Since 1986, he has maintained a private gastroenterology consulting practice in Palo Alto, California, providing comprehensive care to patients with gastrointestinal and liver disorders. Dr. Shields previously served as Assistant Professor of Medicine in the Division of Gastroenterology at Stanford University School of Medicine and served as Director of Endoscopy at Stanford Hospital. Throughout his career, he has remained actively involved in clinical education and physician training. He currently serves as a gastroenterology consultant and clinician at both San Mateo County Medical Center and the Palo Alto Veterans Affairs Health Care System, where he continues to teach medical residents and gastroenterology fellows. Dr. Shields established one of the earliest gastroenterology endoscopy programs associated with Stanford University and has been an early adopter and clinical investigator in capsule endoscopy technology. He has accumulated nearly two decades of experience utilizing capsule endoscopy for the diagnosis and management of small bowel disorders and gastrointestinal bleeding. Dr. Shields earned a Bachelor of Arts degree in Biochemistry with highest honors from the University of California, Santa Barbara, and received his Doctor of Medicine degree from the University of California, San Francisco School of Medicine. He completed his residency training in Internal Medicine at Stanford University School of Medicine and the University of Virginia, followed by a fellowship in Gastroenterology at the University of Virginia. The Board determined that Dr. Shields is an independent director of the Board, and that he satisfies all applicable requirements to serve on the Compensation Committee, including without limitation the applicable requirements of The Nasdaq Stock Market LLC and the Securities Exchange Act of 1934, as amended. On July 1, 2026, Dr. Joanne Imperial stepped down from the Board as a Class I director and as a member of the Compensation Committee of the Board, effective July 1, 2026. Dr. Imperial's decision to resign was not the result of any disagreement with the management or the Board on any matter relating to the Company's operations, policies or practices. Dr. Imperial will continue to serve the Company as an independent consultant.
Reported Earnings • Aug 16Second quarter 2026 earnings released: US$0.15 loss per share (vs US$2.02 loss in 2Q 2025)Second quarter 2026 results: US$0.15 loss per share. Revenue: US$3.64m (up 9.9% from 2Q 2025). Net loss: US$7.48m (loss widened 62% from 2Q 2025). Revenue is forecast to grow 25% p.a. on average during the next 2 years, compared to a 6.0% growth forecast for the Medical Equipment industry in Germany.
お知らせ • Aug 14CapsoVision, Inc. Provides Revenue Guidance for the Second Half of 2026CapsoVision, Inc. provided revenue guidance for the second half of 2026. The company expects revenue in the second half of the year to be higher than in the first half.
お知らせ • Aug 05CapsoVision Announces International Launch of AI Highlights for CapsoCam Plus SystemCapsoVision announced the international launch of AI Highlights for the CapsoCam Plus system. AI Highlights is available within CapsoView and is being introduced in international markets, including the European Union. AI Highlights is designed to support physician review of small bowel capsule endoscopy studies by identifying frames containing suspected clinically relevant findings during the standard video processing workflow. It integrates with CapsoView, CapsoVision's video processing and review software, and supports workflows connected to the Company's CapsoCloud platform. During video processing, the AI algorithm analyzes frames captured by the CapsoCam Plus capsule and identifies frames with suspected clinically relevant findings for physician review. These AI-processed videos may then be reviewed within either CapsoView or CapsoCloud, depending on workflow configuration. AI Highlights is designed to identify and organize frames with suspected clinically relevant findings to support physician assessment as part of the complete study. Where and when available, CapsoCloud enables organizations to securely access AI-processed videos for remote physician review, collaboration, and case management. Depending on workflow configuration and regional availability, studies processed in CapsoView may be securely uploaded to CapsoCloud to support these workflows. AI Highlights is intended to be used by trained healthcare professionals and is not intended to replace clinical judgment. Please refer to the product's Instructions for Use for complete information regarding indications, contraindications, warnings, precautions, and limitations. AI Highlights is being offered as an update to CapsoView and, where applicable, CapsoCloud in markets where these products are authorized for use under applicable regulatory requirements, including the European Union under the Medical Device Regulation (MDR). AI Highlights has not been cleared by the U.S. Food and Drug Administration and is not available for sale in the United States. The Company's portfolio also includes AI Highlights, an AI-assisted workflow feature designed to support physician review of small bowel capsule endoscopy studies. CapsoVision continues to advance its capsule endoscopy platform with AI-assisted capabilities designed to support physician workflow and streamline clinical review. Its next pipeline product, CapsoCam Colon, powered by advanced AI-driven polyp detection, is designed to enable non-invasive colon imaging. With a proprietary platform targeted to expand across multiple GI indications, including esophageal and pancreatic disorders, CapsoVision is advancing a new era in capsule-based diagnostics.
Board Change • Aug 04High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director David Shields was the last director to join the board, commencing their role in 2026. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Jul 31CapsoVision, Inc. to Report Q2, 2026 Results on Aug 13, 2026CapsoVision, Inc. announced that they will report Q2, 2026 results After-Market on Aug 13, 2026
お知らせ • Jul 03CapsoVision, Inc. Announces Board and Committee Changes, Effective July 1, 2026CapsoVision, Inc. announced that on July 1, 2026, the Board of Directors appointed Dr. David Stanley Shields to serve as a Class I director of the Board and as a member of the Compensation Committee of the Board, in each case effective July 1, 2026, to fill the vacancy upon the resignation of Dr. Joanne Imperial. Dr. David S. Shields, age 75, is a board-certified gastroenterologist with more than four decades of experience in academic medicine, clinical gastroenterology, advanced endoscopy, and digestive disease management. Since 1986, he has maintained a private gastroenterology consulting practice in Palo Alto, California, providing comprehensive care to patients with gastrointestinal and liver disorders. Dr. Shields previously served as Assistant Professor of Medicine in the Division of Gastroenterology at Stanford University School of Medicine and served as Director of Endoscopy at Stanford Hospital. Throughout his career, he has remained actively involved in clinical education and physician training. He currently serves as a gastroenterology consultant and clinician at both San Mateo County Medical Center and the Palo Alto Veterans Affairs Health Care System, where he continues to teach medical residents and gastroenterology fellows. Dr. Shields established one of the earliest gastroenterology endoscopy programs associated with Stanford University and has been an early adopter and clinical investigator in capsule endoscopy technology. He has accumulated nearly two decades of experience utilizing capsule endoscopy for the diagnosis and management of small bowel disorders and gastrointestinal bleeding. Dr. Shields earned a Bachelor of Arts degree in Biochemistry with highest honors from the University of California, Santa Barbara, and received his Doctor of Medicine degree from the University of California, San Francisco School of Medicine. He completed his residency training in Internal Medicine at Stanford University School of Medicine and the University of Virginia, followed by a fellowship in Gastroenterology at the University of Virginia. The Board determined that Dr. Shields is an independent director of the Board, and that he satisfies all applicable requirements to serve on the Compensation Committee, including without limitation the applicable requirements of The Nasdaq Stock Market LLC and the Securities Exchange Act of 1934, as amended. On July 1, 2026, Dr. Joanne Imperial stepped down from the Board as a Class I director and as a member of the Compensation Committee of the Board, effective July 1, 2026. Dr. Imperial's decision to resign was not the result of any disagreement with the management or the Board on any matter relating to the Company's operations, policies or practices. Dr. Imperial will continue to serve the Company as an independent consultant.
お知らせ • Jun 29+ 5 more updatesCapsoVision, Inc.(NasdaqCM:CV) dropped from Russell Small Cap Comp Value BenchmarkCapsoVision, Inc.(NasdaqCM:CV) dropped from Russell Small Cap Comp Value Benchmark
Board Change • May 20High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Julia Gouw was the last director to join the board, commencing their role in 2025. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • May 20First quarter 2026 earnings released: US$0.15 loss per share (vs US$2.49 loss in 1Q 2025)First quarter 2026 results: US$0.15 loss per share. Revenue: US$2.79m (flat on 1Q 2025). Net loss: US$7.03m (loss widened 31% from 1Q 2025). Revenue is forecast to grow 27% p.a. on average during the next 2 years, compared to a 5.9% growth forecast for the Medical Equipment industry in Germany.
お知らせ • May 02CapsoVision, Inc. to Report Q1, 2026 Results on May 14, 2026CapsoVision, Inc. announced that they will report Q1, 2026 results After-Market on May 14, 2026
お知らせ • May 01CapsoVision, Inc., Annual General Meeting, Jun 11, 2026CapsoVision, Inc., Annual General Meeting, Jun 11, 2026.
お知らせ • Mar 13CapsoVision, Inc. to Report Q4, 2025 Results on Mar 26, 2026CapsoVision, Inc. announced that they will report Q4, 2025 results After-Market on Mar 26, 2026
お知らせ • Jan 01CapsoVision Announces 510(k) Submission for the Addition of AI-Assisted Reading Module in CapsoCam Plus®?CapsoVision, Inc. announced submission of its 510(k) application to the Food and Drug Administration (FDA) for its proprietary AI-assisted module for CapsoCam Plus®?. The addition of this reading tool will improve the detection of clinically significant pathology, as well as reduce clinician review time. The Company intends for U.S. commercialization activities to commence after the FDA clearance. CapsoVision's CapsoCam Plus capsule endoscopy system is intended for visualization of the small bowel mucosa to detect abnormalities of the small bowel in adults and children aged two years and older. The Company believes that it is a more advanced capsule endoscopy solution compared to competitor systems, both in how it captures and presents images of the GI tract and the clinical workflow and patient experience that it enables.
